Use of Topical Tranexamic Acid and Bacitracin in Dialysis Patients
| Status: | Completed |
|---|---|
| Conditions: | Hospital |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/2/2016 |
| Start Date: | April 2014 |
| End Date: | April 2015 |
| Contact: | Christina Lorenzo, BS |
| Email: | clorenzo@cairr.com |
| Phone: | 858-637-4600 |
This study will investigate how the use of Tranexamic acid and Bacitracin applied to the
bleeding site after the hemodialysis fistula needle is removed will affect skin wound
healing.
bleeding site after the hemodialysis fistula needle is removed will affect skin wound
healing.
Inclusion Criteria:
- Dialysis patients with fistulas (native arterio-venous)
Exclusion Criteria:
- Previous sensitivity to or adverse reaction to Tranexamic acid or Bacitracin.
- Active infection.
- Stenosis of fistula.
We found this trial at
3
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials